In a recent issue of Arthritis Research and Th erapy, Higashi-Kuwata and colleagues elegantly showed evidence that macrophages/monocytes with a profi brotic profi le may be involved in the pathogenesis of systemic sclerosis (SSc) [1] . Early studies of the histopathology of SSc showed that macrophages are found in dermal perivascular and interstitial infi ltrates, particularly promi nent in perivascular infi ltrates of early diff use SSc skin [2] , and in SSc-associated interstitial lung disease [3] . Tissue macrophages show markers of activation in SSc skin expressing increased HLA-DR and plateletderived growth factor type B receptor [4] and MCP-1/ CCL2 [5] , and in bronchoalveolar lavage fl uid secreting increased IL-8 [6] and endothelin-1 [7].
More recent studies have shown that SSc monocytes express allograft inhibitory factor-1 [8] . Data from our group indicate that allograft inhibitory factor-1 expression in circulating monocytes is part of an interferonresponsive gene expression signature in SSc patients [9] (RBC and RL, unpublished observations). Strikingly, in patients showing upregulated interferon-responsive genes, all CD14 + monocytes expressed increased sialoadhesin, suggesting that interferon activates the entire monocyte population. In addition, several genes associated with monocyte/macrophage recruitment and diff erentiation were overexpressed in recent microarray analyses of SSc peripheral blood mononuclear cells, compared with healthy controls [10] .
Macrophages exposed to IFNγ undergo classical activation, referred to as M1, and have powerful antimicrobial activity. In contrast, IL-4 and IL-13 (Th 2 cytokines) switch macrophages to a M2 phenotype, enhancing endocytosis and pinocytosis, repressing proinfl amma tory cytokines and stimulating tissue remodeling [11] . Although the M1/M2 paradigm serves as a useful extension of Th 1/Th 2-mediated immune responses, it is inadequate for completely understanding monocyte responses to cytokines and their diff erentiation into macrophages, because many other mediators impact on this process, including glucocorticoids, toll-like receptor-4 ligands and IL-10 [11] . Although more complex models of monocyte maturation into macrophages have been developed -such as M2a (IL-4/IL-13 activated), M2b (immune complex or toll-like receptor activated) and M2c (IL-10 or glucocorticoid activated) [12] -it may be more appropriate to consider monocytes as responding to a cytokine/innate immune mediator language. Perhaps most relevant in autoimmune disease is the role of type I interferons, as they are also able to activate monocytesstimulating dendritic cell diff erentiation in vitro and, in a model of chronic infl ammation, blocking maturation of Ly6C hi monocytes into Ly6C lo resident monocytes typically recruited to non-infl amed tissues [13] .
In this context, Higashi-Kuwata and colleagues found that CD68, a pan-macrophage indicator, and two markers of macrophage activation, CD163 and CD204, were
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Th e authors also analyzed CD14 + populations in the blood of these patients. Interestingly, they found a minor CD14 hi population of circulating monocytes in SSc patients. Th ese results are notable because CD14 ++ CD16 -/ CX3CR1 lo versus CD14 + CD16 + /CX3CR1 hi in humans (and Ly-6 hi /Gr-1 hi versus Ly-6 lo /Gr-1 lo in the mouse) have been described to represent distinct monocyte subpopulations: the former (CD14 ++ CD16 -) turning into tissue macrophages and possibly dendritic cells or matur ing into CD14 + CD16 + , the major circulating monocyte population; the latter (CD14 + CD16 + ) turning into resi dent tissue monocyte/macrophages [17, 18] . Th e CD14 hi monocyte population described by Higashi-Kuwata and colleagues thus might be normally short-lived CD14 ++ CD16monocytes destined for infl ammatory sites. Based on the recent observations in mice [13] , type I interferon might play a role in this process by blocking maturation of CD14 ++ CD16into CD14 + CD16 + mono cytes, and stimulating CCR2 expression and recruitment into infl amed tissues. Th is hypothesis contrasts with the increased CX3CR1 + cells reported in SSc previously [19] , however, as CX3CR1 + is a marker for CD14 + CD16 + cells and is thought responsible for recruiting these cells as resident tissue macrophages. Both, ie. CD14 + CD16 + CX3CR1 + and CD14 ++ CD16 -CXCR1cells probably represent distinct mono cyte populations, and the resolution of this dilemma is likely to occur through understanding better the underlying cytokine/innate immune stimuli aff ecting SSc monocytes.
Higashi-Kuwata and colleagues further reported that the CD14 hi (CD14 bright or CD14 ++ ) population in SSc patients expresses higher levels of CD163 and CD204. Th e expression of CD163 was greater in SSc patients, whereas CD204 did not distinguish SSc from the healthy controls. In order to further defi ne the CD14 h i population, the authors performed triple staining -confi rming that a minor CD14 hi CD163 + CD204 + population is increased in SSc patients.
Together these results suggest that SSc peripheral blood mononuclear cells develop an anti-infl ammatory and profi brotic M2 phenotype. Further studies will be needed to understand the signals causing these changes and whether they contribute to vascular injury and fi brosis.
